Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note published on Tuesday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

OGEN opened at $0.20 on Tuesday. The stock’s fifty day moving average is $0.23 and its 200-day moving average is $0.29. The company has a market capitalization of $4.23 million, a PE ratio of -0.03 and a beta of 0.87. Oragenics has a one year low of $0.16 and a one year high of $3.43.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.